Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Change in Receivables (2016 - 2025)

Editas Medicine (EDIT) has disclosed Change in Receivables for 11 consecutive years, with $7.5 million as the latest value for Q3 2025.

  • Quarterly Change in Receivables rose 6491.53% to $7.5 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $8.0 million through Sep 2025, up 448.61% year-over-year, with the annual reading at $6.1 million for FY2024, 20.57% up from the prior year.
  • Change in Receivables for Q3 2025 was $7.5 million at Editas Medicine, up from $78000.0 in the prior quarter.
  • The five-year high for Change in Receivables was $16.1 million in Q4 2024, with the low at -$15.8 million in Q1 2025.
  • Average Change in Receivables over 5 years is $109578.9, with a median of -$1000.0 recorded in 2024.
  • The sharpest move saw Change in Receivables tumbled 1133.33% in 2021, then soared 31306.25% in 2022.
  • Over 5 years, Change in Receivables stood at $16000.0 in 2021, then skyrocketed by 31306.25% to $5.0 million in 2022, then skyrocketed by 54.53% to $7.8 million in 2023, then soared by 107.86% to $16.1 million in 2024, then tumbled by 53.27% to $7.5 million in 2025.
  • According to Business Quant data, Change in Receivables over the past three periods came in at $7.5 million, $78000.0, and -$15.8 million for Q3 2025, Q2 2025, and Q1 2025 respectively.